查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1722614

2025-2033年神經調節市場技術、生物材料、應用與地區報告

Neuromodulation Market Report by Technology, Biomaterial, Application, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

2024 年全球神經調節市場規模達 82 億美元。展望未來， IMARC Group預計到 2033 年市場規模將達到 188 億美元，2025-2033 年期間的成長率 (CAGR) 為 9.2%。市場正在經歷強勁成長，這得益於慢性和神經系統疾病患病率的不斷上升、有利監管環境的實施、醫療保健支出的不斷增加、設備技術的顯著進步以及對微創 (MI) 療法的需求不斷成長，同時得到了對研發 (R&D) 計劃的大力投資的支持。

神經調節市場分析：

主要市場促進因素：神經調節市場受到帕金森氏症、慢性疼痛和憂鬱症等慢性疾病和神經系統疾病日益流行的推動。此外，醫療保健支出的增加、提供報銷政策改善的有利法規的實施以及神經調節設備技術的快速進步（包括磁振造影（MRI）安全和可充電設備的開發）正在推動市場成長。

主要市場趨勢：人工智慧 (AI) 和機器學習 (ML) 技術正在融入神經調節設備，從而實現即時監測和治療調整。此外，由於正在進行的研究和成功的臨床試驗，神經調節療法的適應症不斷擴大，從而擴大了市場擴張。

地理趨勢：北美憑藉其先進的醫療保健基礎設施、強大的監管框架和高昂的醫療保健支出在神經調節市場佔據主導地位。其他地區也正在經歷快速成長，這得益於醫療基礎設施的改善、可支配收入的增加以及神經調節療法意識的不斷提高。

競爭格局：神經調節產業的一些主要市場參與者包括雅培實驗室、Bioventus Inc.、波士頓科學公司、Helius Medical Technologies、Integer Holdings Corporation、LivaNova PLC、美敦力公司、MicroTransponder Inc.、Neuronetics、NeuroPace Inc.、NeuroSigma Inc. 和 Nevro Corp. 等。

挑戰與機會：一個主要的挑戰是設備和程序的成本高昂，這可能會限制市場滲透，尤其是在發展中地區。此外，設備植入的複雜性和潛在的副作用也帶來了障礙。然而，神經調節應用範圍不斷擴大，機會也隨之而來，包括對肥胖症和成癮等尚未開發的醫療狀況的潛在治療。此外，增加醫療保健支出為向以前服務不足的地區擴展市場提供了重大機會。

神經調節市場趨勢：

慢性病和神經系統疾病盛行率上升

糖尿病、肥胖症和心血管疾病等慢性疾病以及帕金森氏症、癲癇和憂鬱症等神經系統疾病的發生率不斷上升，是神經調節市場的重要驅動力。根據疾病管制與預防中心 (CDC) 的數據，美國每 10 個成年人中就有 6 個患有慢性疾病。每 10 人就有 4 人患有兩種以上的慢性病。此外，印度約有 21% 的老年人患有至少一種慢性疾病。 17%的農村老年人和29%的城市老年人患有至少一種慢性病。這些健康問題會導致併發症，可以透過神經調節療法進行控制或治療。例如，脊髓刺激 (SCS) 被廣泛用於緩解因背部手術失敗綜合症或複雜的區域疼痛綜合症引起的疼痛。

增加醫療支出

由於醫療保健支出的增加、中產階級人口的不斷成長以及先進醫療保健基礎設施的建立，全球多個國家正在擴大採用神經調節療法。例如，印度23會計年度的醫療保健公共支出佔GDP的2.1%，22會計年度則為2.2%。此外，印度政府還計劃推出一項價值 200 億盧比的信貸獎勵計畫。 50,000 億盧比（68 億美元）用於加強該國的醫療保健基礎設施。同樣，在歐洲，2022 年政府在醫療衛生方面的一般支出達到 12,210 億歐元，佔 GDP 的 7.7%。美國的醫療衛生支出增加了 4.1%，達到 4.5 兆美元，即每人 13,493 美元。此次擴張擴大了神經調節產業的地理覆蓋範圍，並將這些先進的療法引入新的患者群體。

實施優惠報銷政策

神經調節程序報銷政策的持續改善是推動市場成長的主要因素。在許多國家，醫療保險提供者已經修改了他們的政策，將幾種神經調節療法納入其中，因為他們認知到這些療法在治療許多難治性疾病方面的益處。這些變化使得神經調節技術能夠被更廣泛的患者所接受。根據美國人口普查局的數據，2022 年，美國 92.1% 的人（即 3.04 億人）在一年中的某個時間點擁有健康保險。此外，私人醫療保險覆蓋率比公共醫療保險覆蓋率更高，分別為 65.6% 和 36.1%。此外，保險公司也意識到神經調節的長期成本效益，特別是在減少住院時間和藥物使用方面，這擴大了報銷範圍。

神經調節市場細分：

按技術分類：

  • 內部神經調節
  • 脊髓刺激（SCS）
  • 深部腦部刺激（DBS）
  • 迷走神經刺激（VNS）
  • 薦神經刺激（SNS）
  • 胃電刺激（GES）
  • 外部神經調節
  • 經皮神經電刺激（TENS）
  • 經顱磁刺激（TMS）
  • 其他

內部神經調節佔據大部分市場佔有率

根據神經調節市場分析和預測，內部神經調節成為最大的細分市場。其中包括脊髓刺激 (SCS)、深部腦部刺激 (DBS)、薦神經刺激 (SNS) 和迷走神經刺激 (VNS) 等先進療法。它們用於治療多種慢性病和神經系統疾病，包括慢性疼痛、帕金森氏症、尿失禁和大便失禁以及難治性癲癇。此外，內部神經調節在改善患者預後方面的功效已被證實，設備技術的重大進步提高了使用者的安全性和舒適度，臨床應用範圍的擴大也推動了神經調節市場的收入。

依生物材料分類：

  • 金屬生物材料
  • 聚合物生物材料
  • 陶瓷生物材料

金屬生物材料佔據產業最大佔有率

根據神經調節市場報告和概述，金屬生物材料成為最大的細分市場，因為它們在神經調節療法中使用的植入物和設備（如電極和導線）的製造中發揮關鍵作用。金屬生物材料因其優異的電導性、生物相容性和耐用性而受到青睞。它們對於確保神經調節設備的長期可靠性和性能至關重要，特別是那些需要長期植入或受體液和組織影響的設備。除此之外，不斷改善其功能性和安全性的進步，例如增強生物相容性的塗層或降低感染風險的技術，有利於神經調節市場的成長。

按應用分類：

  • 帕金森氏症
  • 癲癇
  • 沮喪
  • 肌張力失調
  • 疼痛管理
  • 其他

帕金森氏症是主要細分市場

根據神經調節市場前景和趨勢，帕金森氏症成為最大的細分市場，反映了神經調節療法在治療慢性神經系統疾病方面的重大影響和實用性。深部腦部刺激 (DBS) 在治療對藥物治療反應不佳的患者方面的應用日益廣泛，這促進了市場的成長。 DBS 有助於緩解震顫、僵硬和運動遲緩等症狀，顯著提高患者的生活品質。此外，神經調節在提供顯著且持續的症狀緩解方面的功效，使得其在臨床環境中廣泛應用，從而催化了神經調節市場佔有率。

按地區分類：

  • 北美洲
  • 美國
  • 加拿大
  • 亞太
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳洲
  • 印尼
  • 其他
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 其他
  • 中東和非洲

北美引領市場，佔據最大的神經調節市場佔有率

該報告還對所有主要區域市場進行了全面的分析，包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。根據報告，北美是神經調節最大的區域市場。

北美佔據神經調節市場的最大佔有率，這歸因於幾個關鍵因素，包括先進的醫療保健基礎設施、強力的監管支持以及對研發 (R&D) 的大量投資。此外，該地區是神經調節行業中一些領先公司的中心，透過不斷的技術進步推動創新和市場成長。此外，慢性病和神經系統疾病的高盛行率，加上完善的醫療保健體係有利於新技術的早期採用，都促進了神經調節市場的收入。

競爭格局：

市場研究報告也對市場競爭格局進行了全面的分析。也提供了所有主要公司的詳細資料。神經調節產業的一些主要市場參與者包括雅培實驗室、Bioventus Inc.、波士頓科學公司、Helius Medical Technologies、Integer Holdings Corporation、LivaNova PLC、美敦力公司、MicroTransponder Inc.、Neuronetics、NeuroPace Inc.、NeuroSigma Inc.、Nevro Corp. 等。

（請注意，這只是關鍵參與者的部分列表，完整列表在報告中提供。）

頂尖的神經調節公司正致力於透過合併、收購和合作等策略性措施來增強其競爭優勢。他們正在投資研發（R&D）來創新和改進他們的神經調節設備。這些創新專注於提高慢性疼痛、帕金森氏症和泌尿系統疾病等疾病治療的精確度、有效性和安全性。此外，產業領導者參與臨床試驗以擴大現有技術的適應症，從而擴大潛在用戶群。他們還優先考慮獲得新市場的監管部門批准，以確保全球範圍內能夠獲得其先進的療法。此外，各大公司正在透過數位平台加強患者和醫生的參與度，以便更好地監測和管理治療結果。這有助於他們順應醫療技術領域數位健康解決方案的更廣泛趨勢，從而對神經調節市場近期的發展和機會產生積極影響。

神經調節市場新聞：

2022年4月，美國波士頓科學公司（Boston Scientific Corporation）的具有可視化軟體STIMVIEW XT的Vercise神經導航儀獲得FDA批准。該設備可讓醫療專業人員查看帕金森氏症患者和接受深部腦部刺激 (DBS) 的患者體內導線或電極的即時位置。

2022 年 12 月，雅培實驗室的 Eterna 脊髓刺激 (SCS) 系統獲得 FDA 批准。它是一種小型可植入、可充電的脊髓刺激器，用於治療慢性疼痛。神經調節裝置採用雅培專有的低劑量 BurstDR 刺激。

本報告回答的關鍵問題

  • 神經調節市場有多大
  • 神經調節市場的未來前景如何
  • 推動神經調節市場的關鍵因素有哪些
  • 哪個地區佔據最大的神經調節市場佔有率
  • 全球神經調節市場領先的公司有哪些

本報告回答的關鍵問題

  • 神經調節市場有多大？神經調節市場的未來前景如何？
  • 推動神經調節市場發展的關鍵因素有哪些？
  • 哪個地區佔據最大的神經調節市場佔有率？
  • 全球神經調節市場領先的公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球神經調節市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依技術

  • 內部神經調節
    • 關鍵部分
      • 脊髓刺激（SCS）
      • 深部腦部刺激（DBS）
      • 迷走神經刺激（VNS）
      • 薦神經刺激（SNS）
      • 胃電刺激（GES）
  • 外部神經調節
    • 關鍵部分
      • 經皮神經電刺激（TENS）
      • 經顱磁刺激（TMS）
      • 其他

第7章：市場區隔：依生物材料

  • 金屬生物材料
  • 聚合物生物材料
  • 陶瓷生物材料

第 8 章：市場區隔：按應用

  • 帕金森氏症
  • 癲癇
  • 沮喪
  • 肌張力失調
  • 疼痛管理
  • 其他

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第10章：SWOT分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第13章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Bioventus Inc.
    • Boston Scientific Corporation
    • Helius Medical Technologies
    • Integer Holdings Corporation
    • LivaNova PLC
    • Medtronic plc
    • MicroTransponder Inc.
    • Neuronetics
    • NeuroPace Inc.
    • NeuroSigma Inc.
    • Nevro Corp.
Product Code: SR112025A5722

The global neuromodulation market size reached USD 8.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 18.8 Billion by 2033, exhibiting a growth rate (CAGR) of 9.2% during 2025-2033. The market is experiencing robust growth, driven by the increasing prevalence of chronic and neurological disorders, imposition of favorable regulatory environment, rising expenditure on healthcare, significant advancements in device technology, and growing demand for minimally invasive (MI) therapies, supported by strong investment in research and development (R&D) initiatives.

Neuromodulation Market Analysis:

Major Market Drivers: The neuromodulation market is driven by the increasing prevalence of chronic diseases and neurological disorders, such as Parkinson's disease, chronic pain, and depression. Moreover, the rising expenditure on healthcare, the implementation of favorable regulations that offer improvements in reimbursement policies, and rapid technological advancements in neuromodulation devices, including the development of magnetic resonance imaging (MRI)-safe and rechargeable devices, are boosting the market growth.

Key Market Trends: There is a trend towards the integration of artificial intelligence (AI) and machine learning (ML) technologies into neuromodulation devices that enable real-time monitoring and adjustments of therapy. Moreover, the expansion of indications for neuromodulation therapies, facilitated by ongoing research and successful clinical trials, is broadening the market expansion.

Geographical Trends: North America dominates the neuromodulation market due to its advanced healthcare infrastructure, robust regulatory framework, and high healthcare expenditure. Other regions are also experiencing rapid growth, driven by improving healthcare infrastructures, increasing disposable incomes, and growing awareness of neuromodulation therapies.

Competitive Landscape: Some of the major market players in the neuromodulation industry include Abbott Laboratories, Bioventus Inc., Boston Scientific Corporation, Helius Medical Technologies, Integer Holdings Corporation, LivaNova PLC, Medtronic plc, MicroTransponder Inc., Neuronetics, NeuroPace Inc., NeuroSigma Inc., and Nevro Corp., among many others.

Challenges and Opportunities: A major challenge is the high cost of devices and procedures, which can limit market penetration, especially in developing regions. Additionally, the complexity of device implantation and potential side effects pose hurdles. However, opportunities lie in the expanding scope of neuromodulation applications, including potential treatments for untapped medical conditions, such as obesity and addiction. Furthermore, increasing healthcare spending presents a significant opportunity for market expansion into previously underserved areas.

Neuromodulation Market Trends:

Rising Prevalence of Chronic Diseases and Neurological Disorders

The heightened incidence of chronic diseases such as diabetes, obesity, and cardiovascular conditions, alongside neurological disorders like Parkinson's disease, epilepsy, and depression, is a significant driver for the neuromodulation market. As per the Centre for Disease Control and Prevention (CDC), 6 in 10 adults in the U.S. are suffering from chronic diseases. And 4 out of 10 people have more than two chronic conditions. Also, about 21% of the geriatric adults in India have at least one chronic disease. 17% of geriatric people in rural areas and 29% in urban areas suffer from at least one chronic disease. These health issues lead to complications that can be managed or treated through neuromodulation therapies. For instance, spinal cord stimulation (SCS) is widely used for pain relief in conditions that result from failed back surgery syndrome or complex regional pain syndrome.

Increasing Expenditure on Healthcare

Several countries across the globe are witnessing increased adoption of neuromodulation therapies owing to rising expenditure on healthcare, the growing population of the middle class, and the establishment of advanced healthcare infrastructures. For instance, India's public expenditure on healthcare touched 2.1% of GDP in FY23 and 2.2% in FY22. Also, the Indian government is planning to introduce a credit incentive program worth Rs. 50,000 crores (US$ 6.8 billion) to boost the country's healthcare infrastructure. Similarly, in Europe, the general government spending on health amounted to €1221 billion or 7.7% of GDP in 2022. The U.S. healthcare spending saw a hike of 4.1%, reaching $4.5 trillion or $13493/person. This expansion is increasing the geographical footprint of the neuromodulation industry and introducing these advanced therapies to new patient populations.

Implementation of Favorable Reimbursement Policies

The ongoing improvements in reimbursement policies for neuromodulation procedures is a main factor driving the market growth. In many countries, health insurance providers have revised their policies to include several neuromodulation therapies as they recognize their benefits in treating many refractory conditions. These changes have made neuromodulation technologies more accessible to a broader range of patients. In 2022, 92.1 percent of people, or 304.0 million in the U.S., had health insurance at some point during the year, as per the U.S. Census Bureau. Moreover, private health insurance coverage was more prevalent than public coverage, at 65.6 percent and 36.1 percent, respectively. Also, insurers are recognizing the cost-effectiveness of neuromodulation in the long term, especially in terms of reduced hospital stays and medication use, which is expanding the scope of reimbursement coverage.

Neuromodulation Market Segmentation:

Breakup by Technology:

  • Internal Neuromodulation
  • Spinal Cord Stimulation (SCS)
  • Deep Brain Stimulation (DBS)
  • Vagus Nerve Stimulation (VNS)
  • Sacral Nerve Stimulation (SNS)
  • Gastric Electrical Stimulation (GES)
  • External Neuromodulation
  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Transcranial Magnetic Stimulation (TMS)
  • Others

Internal neuromodulation accounts for the majority of the market share

Based on the neuromodulation market analysis and forecast, internal neuromodulation emerged as the largest segment. It includes advanced therapies, such as spinal cord stimulation (SCS), deep brain stimulation (DBS), sacral nerve stimulation (SNS), and vagus nerve stimulation (VNS), among others. They are utilized for treating a wide range of chronic conditions and neurological disorders, including chronic pain, Parkinson's disease, urinary and fecal incontinence, and refractory epilepsy. Moreover, the proven efficacy of internal neuromodulations in improving patient outcomes, significant advancements in device technology that enhance user safety and comfort, and the broadening scope of clinical applications are fueling the neuromodulation market revenue.

Breakup by Biomaterial:

  • Metallic Biomaterials
  • Polymeric Biomaterials
  • Ceramic Biomaterials

Metallic biomaterials hold the largest share of the industry

As per the neuromodulation market report and overview, metallic biomaterials stand out as the largest segment, owing to their critical role in the manufacturing of implants and devices used in neuromodulation therapies, such as electrodes and leads. Metallic biomaterials are favored for their superior electrical conductivity, biocompatibility, and durability. They are essential for ensuring the long-term reliability and performance of neuromodulation devices, particularly those that require chronic implantation or are subject to bodily fluids and tissues. Besides this, the ongoing advancements that improve their functionality and safety, such as coatings to enhance biocompatibility or technologies to reduce the risk of infection, are favoring the neuromodulation market growth.

Breakup by Application:

  • Parkinson's Disease
  • Epilepsy
  • Depression
  • Dystonia
  • Pain Management
  • Others

Parkinson's disease represents the leading market segment

According to the neuromodulation market outlook and trends, Parkinson's disease emerged as the largest segment, reflecting the significant impact and utility of neuromodulation therapies in managing chronic neurological disorders. The increasing utilization of deep brain stimulation (DBS) for the treatment of patients who do not respond adequately to pharmacological treatments is enhancing the market growth. DBS helps in alleviating symptoms such as tremors, rigidity, and bradykinesia, significantly enhancing the quality of life for patients. Moreover, the efficacy of neuromodulation in providing substantial and sustained symptom relief, leading to its widespread adoption in clinical settings, is catalyzing the neuromodulation market share.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America leads the market, accounting for the largest neuromodulation market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for neuromodulation.

North America accounted for the largest segment in the neuromodulation market, attributed to several key factors, including advanced healthcare infrastructure, strong regulatory support, and substantial investments in research and development (R&D). Moreover, the region is a hub of some of the leading companies in the neuromodulation industry, which drives innovation and market growth through continuous advancements in technology. Additionally, the high prevalence of chronic diseases and neurological disorders, coupled with a well-established healthcare system that facilitates early adoption of new technologies, is contributing to the neuromodulation market revenue.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the neuromodulation industry include Abbott Laboratories, Bioventus Inc., Boston Scientific Corporation, Helius Medical Technologies, Integer Holdings Corporation, LivaNova PLC, Medtronic plc, MicroTransponder Inc., Neuronetics, NeuroPace Inc., NeuroSigma Inc., Nevro Corp., etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The top neuromodulation companies are engaged in enhancing their competitive edge through strategic initiatives, such as mergers, acquisitions, and partnerships. They are investing in research and development (R&D) to innovate and improve their neuromodulation devices. These innovations focus on increasing the precision, effectiveness, and safety of therapies for conditions like chronic pain, Parkinson's disease, and urinary disorders. Additionally, industry leaders are involved in clinical trials to expand the indications for existing technologies, thereby broadening the potential user base. They are also prioritizing obtaining regulatory approvals in new markets to ensure global access to their advanced therapies. Furthermore, major companies are enhancing patient and practitioner engagement through digital platforms that facilitate better monitoring and management of therapy outcomes. This helps them align with the broader trend toward digital health solutions in medical technology, thereby positively impacting the neuromodulation market's recent development and opportunities.

Neuromodulation Market News:

In April 2022, Boston Scientific Corporation (US) received FDA approval for its Vercise Neural Navigator with visualization software, STIMVIEW XT. The device allows medical professionals to view the real-time location of leads, or electrodes, in patients with Parkinson's disease and those undergoing deep brain stimulation (DBS).

In December 2022, Abbott Laboratories received FDA approval for its Eterna spinal cord stimulation (SCS) system. It is a small implantable and rechargeable spinal cord stimulator for treating chronic pain. The neuromodulation device utilizes Abbott's proprietary low-dose BurstDR stimulation.

Key Questions Answered in This Report

  • 1.How big is the neuromodulation market?
  • 2.What is the future outlook of neuromodulation market?
  • 3.What are the key factors driving the neuromodulation market?
  • 4.Which region accounts for the largest neuromodulation market share?
  • 5.Which are the leading companies in the global neuromodulation market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Neuromodulation Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Internal Neuromodulation
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Spinal Cord Stimulation (SCS)
      • 6.1.2.2 Deep Brain Stimulation (DBS)
      • 6.1.2.3 Vagus Nerve Stimulation (VNS)
      • 6.1.2.4 Sacral Nerve Stimulation (SNS)
      • 6.1.2.5 Gastric Electrical Stimulation (GES)
    • 6.1.3 Market Forecast
  • 6.2 External Neuromodulation
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Transcutaneous Electrical Nerve Stimulation (TENS)
      • 6.2.2.2 Transcranial Magnetic Stimulation (TMS)
      • 6.2.2.3 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Biomaterial

  • 7.1 Metallic Biomaterials
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Polymeric Biomaterials
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Ceramic Biomaterials
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Parkinson's Disease
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Epilepsy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Depression
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Dystonia
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Pain Management
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bioventus Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Boston Scientific Corporation
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Helius Medical Technologies
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Integer Holdings Corporation
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 LivaNova PLC
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Medtronic plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 MicroTransponder Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Neuronetics
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 NeuroPace Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
    • 14.3.11 NeuroSigma Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 Nevro Corp.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials

List of Figures

  • Figure 1: Global: Neuromodulation Market: Major Drivers and Challenges
  • Figure 2: Global: Neuromodulation Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Neuromodulation Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Neuromodulation Market: Breakup by Technology (in %), 2024
  • Figure 5: Global: Neuromodulation Market: Breakup by Biomaterial (in %), 2024
  • Figure 6: Global: Neuromodulation Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Neuromodulation Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Neuromodulation (Internal Neuromodulation) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Neuromodulation (Internal Neuromodulation) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Neuromodulation (External Neuromodulation) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Neuromodulation (External Neuromodulation) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Neuromodulation (Metallic Biomaterials) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Neuromodulation (Metallic Biomaterials) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Neuromodulation (Polymeric Biomaterials) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Neuromodulation (Polymeric Biomaterials) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Neuromodulation (Ceramic Biomaterials) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Neuromodulation (Ceramic Biomaterials) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Neuromodulation (Parkinson's Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Neuromodulation (Parkinson's Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Neuromodulation (Epilepsy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Neuromodulation (Epilepsy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Neuromodulation (Depression) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Neuromodulation (Depression) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Neuromodulation (Dystonia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Neuromodulation (Dystonia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Neuromodulation (Pain Management) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Neuromodulation (Pain Management) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Neuromodulation (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Neuromodulation (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: North America: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: North America: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: United States: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: United States: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Canada: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Canada: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Asia-Pacific: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Asia-Pacific: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: China: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: China: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Japan: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Japan: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: India: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: India: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: South Korea: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: South Korea: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Australia: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Australia: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Indonesia: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Indonesia: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Others: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Others: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Europe: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Europe: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Germany: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Germany: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: France: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: France: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: United Kingdom: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: United Kingdom: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Italy: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Italy: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Spain: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Spain: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Russia: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Russia: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Others: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Others: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Latin America: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Latin America: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Brazil: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Brazil: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Mexico: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Mexico: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Others: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Others: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Middle East and Africa: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Middle East and Africa: Neuromodulation Market: Breakup by Country (in %), 2024
  • Figure 78: Middle East and Africa: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Global: Neuromodulation Industry: SWOT Analysis
  • Figure 80: Global: Neuromodulation Industry: Value Chain Analysis
  • Figure 81: Global: Neuromodulation Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Neuromodulation Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Neuromodulation Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 3: Global: Neuromodulation Market Forecast: Breakup by Biomaterial (in Million USD), 2025-2033
  • Table 4: Global: Neuromodulation Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Neuromodulation Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Neuromodulation Market: Competitive Structure
  • Table 7: Global: Neuromodulation Market: Key Players